Anca-associated vasculitides: recommendations of the french vasculitis study group on the use of immunosuppressants and biotherapies for remission induction and maintenance.

ANCA-ASSOCIATED VASCULITIDES: RECOMMENDATIONS OF THE FRENCH VASCULITIS STUDY GROUP ON THE USE OF IMMUNOSUPPRESSANTS AND BIOTHERAPIES FOR REMISSION INDUCTION AND MAINTENANCE. Presse Med. 2020 Jul 06;:104031 Authors: Terrier B, Charles P, Aumaître O, Belot A, Bonnotte B, Crabol Y, Durel CA, Ebbo M, Jourde-Chiche N, Lega JC, Puéchal X, Pugnet G, Quemeneur T, Ribi C, Samson M, Vandergheynst F, Guillevin L, French Vasculitis Study Group/pour le Groupe Français d’Etude des Vascularites (GFEV) Abstract Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience. PMID: 32645418 [PubMed - as supplied by publisher]
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research